Dendreon CEO resigns

August 15 is John Johnson's last day as president and CEO.

June 10, 2014

5:45 pm

Dendreon CEO John Johnson is calling it quits. The Seattle manufacturer of prostate cancer drug Provenge announced Monday that Johnson was leaving for personal reasons. Douglas Watson has replaced Johnson as chairman of the board. Johnson will remain president and CEO through August 15.

The Street’s Adam Feuerstein noted Monday that Johnson is leaving the beleaguered company as it is subsumed by debt, and says the company will make its June $28 million payment, but “has no means to pay the $560 million in debt due in 2016.”

Johnson was named CEO in February 2013.

From Our Partners

Omnichannel activation without omniburden

Partner Content

Omnichannel activation without omniburden

Explore solutions for practically implementing omnichannel approaches into your go-to-market activation.

Taking a patient-centric approach to privacy

Partner Content

Taking a patient-centric approach to privacy

This podcast will explore ways to deliver tailored content that activates, educates and empowers patients while prioritizing privacy and consent.

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.

Partner Content

The new brand.com experience

How healthcare manufacturers can improve customer engagement, drive high-value activity and inform future strategy with conversational AI.